Voluntary announcement - enter into strategic biosimilars partnership with STADA
Filed with HKEX · Stock code 1177 · · 3 pages · English
Summary by 6ix AI
The partnership involves an exclusive license for STADA to commercialize a specific biosimilar in multiple territories, with potential milestone payments and profit sharing for Sino Biopharmaceutical's subsidiary. This collaboration is part of Sino Biopharmaceutical's broader globalization strategy, aiming to expand its international partnerships and biosimilar pipeline. The announcement highlights the company's commitment to innovation and high-quality manufacturing in the biologics sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sino Biopharmaceutical Limited on 6ix
Earlier from Sino Biopharmaceutical
- Notification letter and request form for non-registered shareholders
- Notification letter and reply form for registered shareholders
- 2026 Interim report
- Voluntary announcement - acceptance of new drug application for TQH2722 injection
- Voluntary announcement - acceptance of new drug application for TQB2102 injection "HER2 bispecific adc"
Later from Sino Biopharmaceutical
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - completion of all subjects enrollment in the phase iii registrational clinical trial of TQC3721 inhalation suspension "PDE3/4 inhibitor"
- Next day disclosure return
- Voluntary announcement - latest research results on tq-A3334 "TLR7 agonist" and bepirovirsen "aso" to be presented at 2026 aasld
- Voluntary announcement - completion of all participants enrollment in the phase iii registrational clinical trial of TQC2731 injection "tslp monoclonal antibody" for chronic sinusitis with nasal polyps
Follow Sino Biopharmaceutical into a list and get an email when it puts out news.
Follow Sino Biopharmaceutical